Get Live Data

The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE
Roundtable Discussion; The Future of Mineral Sands
Roundtable Discussion; The Future of Mineral SandsView Video

Latest Share Chat

  2. Share Prices
  3. Syncona Share Price
  4. Syncona Share News
  5. UK earnings, trading statements calendar - next 7 days

Pin to quick picksSyncona Share News (SYNC)

Syncona Information

Share Price Information for Syncona (SYNC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 120.40
Bid: 120.00
Ask: 120.40
Change: -1.60 (-1.31%)
Spread: 0.40 (0.333%)
Open: 120.20
High: 121.60
Low: 120.20
Prev. Close: 122.00
SYNC Live PriceLast checked at -
Syncona is an Investment Trust

To deliver superior long-term capital appreciation from investments in life science businesses, leading long-only and alternative investment funds and managed accounts across multiple asset classes.

Find out More

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK earnings, trading statements calendar - next 7 days

Thu, 09th Nov 2023 15:44

Friday 10 November 
Allianz Technology Trust PLCQ3 Results
Wheaton Precious Metals CorpQ3 Results
Monday 13 November 
Bank of Cyprus Holdings PLCQ3 Results
British Land Co PLCHalf Year Results
Kainos Group PLCHalf Year Results
Team Internet Group PLCQ3 Results
Tuesday 14 November 
ActiveOps PLCHalf Year Results
Babcock International Group PLCHalf Year Results
Bank of Georgia Group PLCQ3 Results
Castings PLCHalf Year Results
ConvaTec Group PLCTrading Statement
DCC PLCHalf Year Results
Forterra PLCHalf Year Results
Gear4Music PLCHalf Year Results
Genel Energy PLCTrading Statement
HydrogenOne Capital Growth PLCQ3 Results
Hill & Smith PLCTrading Statement
Imperial Brands PLCFull Year Results
Informa PLCTrading Statement
Land Securities Group PLCHalf Year Results
Oxford Instruments PLCHalf Year Results
Picton Property Income LtdHalf Year Results
Renalytix PLCQ1 Results
Vesuvius PLCTrading Statement
Vodafone Group PLCHalf Year Results
Wise PLCHalf Year Results
Wednesday 15 November 
Diversified Energy Co PLCTrading Statement
Experian PLCHalf Year Results
Fuller, Smith & Turner PLCHalf Year Results
Genuit Group PLCTrading Statement
Intermediate Capital Group PLCHalf Year Results
Ninety One PLC and LtdHalf Year Results
Renold PLCHalf Year Results
SSE PLCHalf Year Results
Synthomer PLCTrading Statement
Tracsis PLCFull Year Results
Tullow Oil PLCTrading Statement
Warehouse REIT PLCHalf Year Results
Thursday 16 November 
Assura PLCHalf Year Results
Atalaya Mining PLCQ3 Results
Aviva PLCTrading Statement
Burberry Group PLCHalf Year Results
Close Brothers Group PLCTrading Statement
CMC Markets PLCHalf Year Results
Crest Nicholson Holdings PLCTrading Statement
Halma PLCHalf Year Results
Great Portland Estates PLCHalf Year Results
Kier Group PLCTrading Statement
International Distributions Services PLCHalf Year Results
Investec PLC and LtdHalf Year Results
Liontrust Asset Management PLCHalf Year Results
Manolete Partners PLCHalf Year Results
Melrose Industries PLCTrading Statement
Norcros PLCHalf Year Results
Premier Foods PLCHalf Year Results
Qinetiq Group PLCHalf Year Results
Spirax-Sarco Engineering PLCTrading Statement
Syncona LtdHalf Year Results
Tatton Asset Management PLCHalf Year Results
Tyman PLCTrading Statement
United Utlities Group PLCHalf Year Results
Young & Co's Brewery PLCHalf Year Results
  
Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
3 May 2024 09:14

LONDON BROKER RATINGS: Jefferies cuts AJ Bell; Deutsche likes ConvaTec

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning and Thursday:

Read more
11 Apr 2024 14:22

Syncona agrees to sell stake in investee company for GBP7.4 million

(Alliance News) - Syncona Ltd on Thursday said it has reached an agreement to sell one of its portfolio companies to US biotechnology firm, Century Therapeutics Inc.

Read more
4 Apr 2024 17:06

IN BRIEF: Syncona notes investee Achilles's annual loss narrows

Syncona Ltd - London-based investor in healthcare companies - Notes that the loss of investee and clinical-stage biopharmaceutical company Achilles Therapeutics PLC narrows by 2.7% to USD68.2 million in 2023 from USD71.1 million in 2022. General and administrative costs contract by 19% to USD17.0 million from USD21.1 million. According to Syncona's website, the company has a 25% stake in Achilles.

Read more
14 Mar 2024 14:16

Syncona portfolio company Autolus posts widened loss for 2023

(Alliance News) - Syncona Ltd on Thursday noted the 2023 results of one of its life science portfolio companies, which showed a widened loss and an increase in annual expenses.

Read more
12 Feb 2024 18:01

IN BRIEF: Freeline shareholders approve Syncona acquisition

Syncona Ltd - London-based investor in healthcare companies - Freeline Therapeutics Holdings PLC shareholders approve acquisition by Syncona.

Read more
8 Feb 2024 13:45

UPDATE: Syncona portfolio strengthens thanks to Autolus

(Alliance News) - Syncona Ltd on Thursday said its portfolio company Autolus Therapeutics PLC has struck a deal to work with BioNTech to commercialise its CAR-T programmes.

Read more
8 Feb 2024 09:41

Syncona portfolio strengthens in third quarter thanks to Autolus

(Alliance News) - Syncona Ltd on Thursday reported a recent increase to the value of its portfolio, as the company said it was in a strong position to push forward its main life science companies.

Read more
8 Feb 2024 09:04

Syncona NAV grows in Q3

(Sharecast News) - Life sciences investor Syncona said on Thursday that its net asset value had grown in the three months ended 31 December, driven by a prioritisation of capital allocation across its portfolio to enable the delivery of key inflection points.

Read more
22 Jan 2024 12:19

IN BRIEF: Syncona notes FDA acceptance of Autolus's BLA for obe-cel

Syncona Ltd - London-based investor in healthcare companies - The US Food & Drug Administration accepts Autolus Therapeutics PLC's biologics licence application for obe-cel for patients with relapsed/refractory adult B-cell acute lymphoblastic leukaemia. The FDA has set a target action date of November 16 for reviewing the application, Syncona says. Further, Autolus is on track to submit a marketing authorisation application to the EU's European Medicines Agency in the first half of 2024.

Read more
19 Jan 2024 08:36

Syncona says Freeline trial for Gaucher disease treatment positive

(Alliance News) - Syncona Ltd on Friday noted Freeline Therapeutics Holdings PLC's positive data for Gaucher disease treatment.

Read more
4 Dec 2023 09:37

IN BRIEF: Syncona notes Beacon's "encouraging" AGTC-501 trial data

Syncona Ltd - London-based investor in healthcare companies - Says portfolio company, Beacon Therapeutics has presented three-month data from the phase 2 Skyline trial of its viral vector-based gene therapy AGTC-501 in X-linked retinitis pigmentosa at the Floretina ICOOR 2023 Congress in Rome. Notes AGTC-501 shows an "encouraging efficacy profile", showing a "significant improvement" in retinal sensitivity. Adds that there are no clinically significant safety events related to AGTC-501.

Read more
27 Nov 2023 19:03

TRADING UPDATES: Molten Ventures completes raise; Saietta proposes one

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

Read more
22 Nov 2023 14:30

IN BRIEF: Syncona agrees to buyout deal with Freeline Therapeutics

Syncona Ltd - London-based investor in healthcare companies - Agrees to acquire all remaining stock in investee Freeline Therapeutics Holdings PLC for USD6.50 in cash per share, valuing Freeline at approximately USD28.3 million. Syncona currently owns 49.7% of shares in Freeline. The company will provide up to USD15 million of financing in conjunction with the acquisition to enable Freeline to meet its near-term cash requirements and continue advancing its lead programme FLT201, a potential gene therapy for Gaucher disease.

Read more
16 Nov 2023 10:34

Syncona reports declining asset value as investment head steps down

(Alliance News) - Syncona Ltd on Thursday said net asset value decreased as it swung to a negative return in its latest half year, but that it is well-positioned for future growth thanks to its "rich pipeline".

Read more
16 Nov 2023 08:44

Syncona net asset value falls, co-founder steps down

(Sharecast News) - Life science specialist Syncona reported a net asset value of £1.2bn at the end of its first half on Thursday, down from £1.25bn on 31 March, with a net asset value return of -4.2% during the period.

Read more
12345678910

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.